Goldman Sachs initiated coverage of Genscript Biotech with a Buy rating and HK$29.34 price target, implying 31% upside from current levels. The analyst says cell and gene therapies are seeing expanded adoption which could drive up the market potential. The company demonstrates potential solutions that could be critical in driving more explosive growth of cell and gene therapies particularly autologous cell therapies, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>